Abstract
A recombinant fusion protein targeting the urokinase-type plasminogen activator receptor (uPAR) and delivering a potent catalytic toxin has the advantage of simultaneously targeting both over-expressed uPAR on glioblastoma cells and on the tumor neovasculature. Such a hybrid protein was synthesized consisting of the noninternalizing amino-terminal fragment (ATF) of urokinase-type plasminogen activator (uPA) for binding, and the catalytic portion of diphtheria toxin (DT) for killing, and the translocation enhancing region (TER) of DT for internalization. The protein was highly selective for human glioblastoma in vitro and in vivo. In vivo, this DT/ATF hybrid called DTAT caused the regression of small subcutaneous uPAR-expressing tumors with minimal toxicity to critical organs. In vitro, DTAT killed only uPAR-positive glioblastoma cell lines and human endothelial cells in the form of the HUVEC cell line. Killing was selective and blockable with specific antibody. DTAT was highly effective against tumor cells cultured from glioblastoma multiforme patients and in vitro mixing experiments combining DTAT with DTIL13 another highly effective anti-glioblastoma agent showed that the mixture was as toxic as the most potent immunotoxin. In this article, we review our progress to date with DTAT.
Similar content being viewed by others
References
Salcman M: Epidemiology and factors affecting survival. In: Appuzo MLJ (ed) Malignant Cerebral Glioma. American Association of Neurological Surgeons, Park Ridge, Il 1980, pp 95–110
Frankel SA, German WJ: Glioblastoma multiforme (review of 219 cases with regard to natural history, pathology, diagnostic methods, and treatment). J Neurosurg 15: 489–503, 1985
Walker AE, Robins M, Weinfeld FD: Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 35: 219–226, 1985
Mahaley MS, Mettlin C, Natarajan N, Laws ER, Peace BB: National survey patterns of care for brain-tumor patients. J Neurosurg 71: 826–836, 1989
Davies E, Clarke C, Hopkins A: Malignant cerebral glioma-I: survival, disability, and morbidity after radiotherapy. Br Med J 313: 1507–1512, 1996
Rutigliano MJ, Lunsford LD, Kondziolka D et al.: The cost effectiveness of stereotactic radiosurgery versus surgical resection in the treatment of solitary metastatic brain tumors. Neurosurgery 37: 445–455, 1995
Kirby S, Macdonald D, Fisher B et al.: Pre-radiation chemotherapy for malignant glioma in adults. Can J Neurol Sci 23: 123–127, 1996
Kristensen CA, Kristjansen PE, Hansen HH: Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 10: 1498–1502, 1992
McAllister LD, Doolittle ND, Gustadisegni PE et al.: Cognitive outcomes and long-term follow-up after enhanced chemotherapy delivery for primary central nervous system lymphomas. Neurosurgery 46: 51–61, 2000
Oddens EA, Shapiro WR: Brain tumors. Cancer Chemo Biol Response Modif 12: 615–633, 1991
Packer RJ: Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. Ann Neurol 28: 823–828, 1990
Tomlinson FH, Scheithauer BW, Meyer FB et al.: Medulloblastoma I. Clinical, diagnostic, and therapeutic overview. J Child Neurol 7: 142–155, 1992
Williams PC, Henner WD, Roman-Goldstein S, Dahlborg SA et al.: Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood– brain barrier in the treatment of intracranial neoplasms. Neurosurgery 37: 17–28, 1995
Walker MD, Green SB, Byar DP et al.: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323–1329, 1980
Nazarro JM, Neuwalt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73: 331–344, 1990
Salcman M: The morbidity and mortality of brain tumors. A perspective on recent advances in therapy. Neurol Clin 3: 229–257, 1985
Shapiro WR: Treatment of neuroectodermal brain tumors. Ann Neurol 12: 231–237, 1982
Hall WA, Djalilian HR, Sperduto PW, Cho KW et al.: Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 13: 1642–1648, 1995
Hall WA, Fodstad Ø: Immunotoxins and central nervous system neoplasias. J Neurosurg 76: 1–12, 1992
Gonzalez-Vitale J, Garcia-Bunnuel R: Meningeal carcinomatosis. Cancer 37: 2906–2911, 1976
Olson M, Chernik N, Posner J: Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 30: 122–137, 1974
Muraszko K, Sung C, Walbridge S, Greenfield L et al.: Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents. Cancer Res 53: 3752–3757, 1993
Bindal RK, Sawaya R, Leavens ME, Lee JJ: Surgical treatment of multiple brain metastases. J Neurosurg 79: 210–216, 1993
Nussbaum ES, Djalilian HR, Hall WA: Brain metastases: histology, multiplicity, surgery, and survival. Cancer 78(8): 1781–1788, 1996
Patchell RA, Tibbs PA, Walsh JW et al.: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322: 494–500, 1990
Greene GM, Hitchon PW, Schelper RL, Yuh W, Dyste GN: Diagnostic yield in CT-guided stereotactic biopsy of gliomas. J Neurosurg 71: 494–497, 1989
Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA et al.: Imaging-based stereotactic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 66: 865–874, 1987
Burger PC, Heinz ER, Shibata T, Kleihues P: Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68: 698–704, 1988
Bergstrom M, Collins P, Ehrin E: Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga] EDTA, [11C] glucose, and [11C] methionine. J Comput Assist Tomogr 7: 1062–1066, 1983
Earnest F, Kelly PJ, Scheithauer BW, Kall BA et al.: Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166: 823–827, 1988
Kroll RA, Neuwelt EA: Outwitting the blood–brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42(5): 1083–1099, 1998
Skipper H: Historic milestones in cancer biology: a few that are important to cancer treatment (revisited). Semin Oncol 6: 506–514, 1979
Morrow C, Cowan K: Drug resistance and cancer. Adv Exp Med Biol 330: 287–305, 1993
Frankel AE, Kreitman RJ, Sausville EA: Targeted toxins. Clin Cancer Res 6: 326–333, 2000
Shockley TR, Lin K, Sung C, Nagy JA, Tompkins RG, Dedrick RL, Dvorak HF, Yarmush ML: A quantitative analysis of tumor-specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 52: 357–366, 1992
Sung C, Shockley TR, Morrison PF, Dvorak HF, Yarmush ML, Dedrick RL: Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res 52: 377–384, 1992
Baxter LT, Yuan F, Jain RK: Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and 72 haptens: comparison with experimental data. Cancer Res 52: 5838–5844, 1992
Jain RK: Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81: 1989
Oldfield EH, Youle RJ: Immunotoxins for brain tumor therapy. Curr Top Microbiol Immunol 234: 97–114, 1998
Ehlrich P: The relationship between chemical constitution, distribution, and pharmacological action. In: Himmelweit F, Marquardt M, Dale H (eds) The Collected Papers of Paul Ehrlich, vol 1, Pergamon Press, Elmsford, NY, 1956, pp 596–618
Jansen FK, Blythman HE, Carriere D et al.: Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 62: 185–216, 1982
Vitetta E, Fulton R, May R et al.: Redesigning major positions to create antitumor reagents. Science 238: 1098–1104, 1987
Fostad Ø, Pihl A: Synergistic effect of ricin in combination with daunorubicin, cis-dichlorodiammineplatinum (II) and vincristine in systemic L1210 Leukemia. Cancer Res 42: 2152–2158, 1982
Remsen LG, Trail PA, HellsotrÖm I, HellsotrÖm KE, Neuwelt EA: Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 46: 704–709, 2000
Sjogren HO, Isaksson M, Willner D et al.: Antitumor activity of carcinoma-reactive BR96–doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res 57: 4530–4536, 1997
Trail PA, Willner D, Lasch SJ et al.: Cure of xenografted human carcinomas by BR96–doxorubicin immunoconjugates. Science 261: 212–215, 1993
Remsen LG, Marquez C, Garcia R et al.: Efficacy after sequencing of brain radiotherapy enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model. Int J Radiat Oncol Biol Phys 51: 1045–1049, 2001
Akabani G, Cokgor I, Coleman RE, Trotter DG et al.: Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 46(4): 947–958, 2000
Riva P, Franceschi G, Arista A et al.: Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience.Cancer 80(Suppl. 12): 2733–2742, 1997
Kemshead JT, Hopkins K, Pizer B et al.: Dose escalation with repeated intratethecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies. Br J Cancer 77: 2324–2330, 1998
Pizer BL, Papanastassiou V, Hancock J et al.: A pilot study of monoclonal targeted radiotherapy in the treatment of central nervous system leukemia in children. Br J Haematol 77: 466–472, 1991
Westlin JE, Snook D, Nilsson S et al.: Intravenous and intratumoural therapy of patients with malignant gliomas with 90Yttrium labelled monoclonal antibody MUC 2–63. In: Epenetos A (ed) Monoclonal Antibodies: Applications in Clinical Oncology. Chapman and Hall Medica, London, UK, 1992, pp 17–25
Papanastassiou V, Pizer BL, Coakam HB et al.: Treatment of recurrent and cystic malignant glioma by a single intracavitary injection of I-131 monoclonal antibody: feasibility, pharmacokinetics, and dosimetry. Br J Cancer 67: 144–151, 1993
Youle RJ: Immunotoxins for central nervous system malignancy. Cancer Biol 7: 65–70, 1996
Siegall CB: Targeted toxins as anticancer agents. Cancer 74: 1006–1012, 1994
Faillot T, Magdelenat H, Mady E et al.: A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 39: 478–483, 1996
Manome Y, Watanabe M, Ohno T: The effect of immunotoxin against human glioma cells. Neurochir 32: 146–149, 1989
Zalutsky MR, Archer GE, Garg PK et al.: Chimeric antitenascin antibody 81C6: increased tumor localization compared with its murine parent. Nucl Med Biol 23: 449–458, 1996
Hall WA: Immunotoxin therapy. Neurosurg Clin N Amer 7: 537–546, 1996
Engebraaten O, Hjortland GO, Juell S et al.: Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 97: 846–852, 2002
Frainkel AE, Tagge EP, Willingham MC: Clinical trials of targeted toxins. Cancer Biol 6: 307–317, 1995
Martell LA, Agrawal A, Ross DA, Murasko KM: Efficacy of transferin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 53: 1348–1353, 1993
Zovickian J, Johnson VG, Youle RJ: Potent and specific killing of human malignant brain tumor cells by an anti-transferin receptor antibody-ricin immunotoxin. J Neurosurg 66: 850–861, 1987
Mujoo K, Cheung L, Murray JL: Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin. Cancer Immunol Immunother 40: 339–345, 1995
Baxter LT, Zhu H, Mackensen DG, Jain RK: Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54: 1517–1528, 1994
Yokota T, Milenic DE, Whitlow M, Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402–3408, 1992
Joshi BH, Leland P, Asher A et al.: In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res 61: 8058–8061, 2001
Rand RW, Kreitman RJ, Patronas N et al.: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with highgrade glioma. Clin Cancer Res 6: 2157–2165, 2000
Yazdi PT, Murphy RM: Quantitative analysis of protein synthesis inhibition by transferrin–toxin conjugates. Cancer Res 54: 6387–6394, 1994
Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3: 1362–1368, 1997
Kawakami K, Kawakami M, Puri RK: Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol 21: 299–310, 2001
Debinski W, Obiri NI, Powers SK et al.: Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1: 1253–1258, 1995
Puri RK, Hoon DS, Leland P et al.: Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytomas. Cancer Res 56: 5631–5637, 1996
Pastan I, Fitzgerald D: Recombinant toxins for cancer treatment. Science 254: 1173–1177, 1992
Johnson VG, Wilson D, Greenfield L et al.: The role of the diphtheria toxin receptor in cytosol translocation. J Biol Chem 263: 1295–1300, 1988
Hall WA: Targeted toxin therapy. In: Kornblith PL, Walker MD (eds) Advances in Neuro-Oncology II. Futura Armonk, NY, 1997, pp 505–516
Fitzgerald DJ, Willingham MC, Cardarelli CO et al.: Amonoclonal antibody–Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci USA 84: 4288–4292, 1987
Hertler AA, Frankel AE: Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol 7: 1932–1942, 1989
McNally NJ: Enhancement of chemotherapy agents. Int J Radiat Oncol Biol Phys 8: 593–598, 1982
Jain RK, Baxter LT: Mechanism of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48: 7022–7032, 1988
Baxter LT, Jain RK: Transport of fluid and macromolecules in tumors I. Role of interstitial pressure and convection. Microvasc Res 37: 77–102, 1989
Jain RK: Transport of molecules in the tumor interstitium: a review. Cancer Res 47: 3039–3051, 1987
Wiig H, Tveit E, Hultborn R et al.: Interstitial fluid pressure in DMBA-induced rat mammary tumors. Scand J Clin Lab Invest 42: 159–164, 1982
Misiewicz M: Microvascular and interstitial pressures in normal and neoplastic tissues. M.S. Thesis Pittsburgh, Carnegie Mellon University, 1986
Sylven B, Bois I: Protein content and enzymatic assays of interstitial fluid from some normal tissues and transplanted mouse tumors. Cancer Res 20: 831–835, 1960
Weistein JN, Eger RR, Covell DG et al.: The pharmacology of monoclonal antibodies. Ann NY Acad Sci 507: 199–210, 1987
Dedrick RL, Flessner MF: Pharmacokinetic considerations of monoclonal antibodies. Prog Clin Biol Res 288: 429–438, 1989
Capone PM, Papsidero LD, Chu TM:Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors. J Natl Caner Inst 72: 673–677, 1984
Wen DY, Hall WA, Conrad J, Godal A, Florenes VA, Fodstad O: In vitro and in vivo variation in transferring receptor expression on a human medulloblastoma cell line. Neurosurgery 36: 1158–1163, 1995
Peter RU, Beetz A, Ried C et al.: Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation. Radiat Res 136: 65–70, 1993
Schmidt-Ulrich RK, Valerie K, Chan W et al.: Expression of oestrogen receptor and transforming growth factor in MCF-7 cells after exposure to fractionated irradiation. Int J Radiat Biol 61: 405–415, 1992
Schmidt-Ulrich RK, Valerie K, Chan W et al.: Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys 29: 813–819, 1994
Schmidt-Ulrich RK, Valerie K, Chan W et al.: Radiationinduced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 145: 81–85, 1996
Vallera DA, Panoskaltsis-Mortari A, Yost C, Ramakrishnan S, Eide CR, Kreitman R, Nicholls PJ, Pennell C, Blazar BR: Anti-graft versus host disease effect of DT390-anti-CD3sFv, a single chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T cell receptor. Blood 88: 2342, 1996
Chan C-H, Blazar BR, Eide CR, Kreitman RJ, Vallera DA: A murine cytokine fusion toxin specifically targeting the murine GM-CSF receptor on normal committed bone marrow progenitor cells and GM-CSF dependent tumor cells. Blood 86: 2732, 1995
Chan CH, Blazar BR, Eide CR, Greenfield L, Kreitman RJ, Vallera DA: Reactivity of murine cytokine fusion toxin, DT390-mIL-3, with bone marrow progenitor cells 1,2. Blood 88: 1445, 1996
Colombatti M, Greenfield L, Youle RJ: Cloned fragment of diphtheria toxin linked toT-cell-specific antibody identifies regions of B chain active in cell entry. J Biol Chem 261: 3030–3035, 1986
Williams DP, Snider CE, Strom TB, Murphy JR: J Biol Chem 265: 11885–11889, 1990
Nichols P, Youle RJ: Structure of diphtheria toxin as a guide to rational design. In: Frankel AE (ed) Genetically Engineered Toxins. Marcel Dekker, NewYork, 1992, p 339
Collier JR: Structure–activity relationships in diphtheria toxin and Pseudomonas aeruginosa exotoxin A. In: Frankel AE (ed) Immunotoxins. Kluwer Academic Publishers, Norwell, MA, 1988, p 25
Vallera DA, Kuroki DW, Panoskaltsis-Mortari A, Buchbaum DJ, Blazar BR: Molecular modification of recombinant immunotoxin inducing terminal cysteine bridging reduces toxicity and enhances the anti-GVHD effect in a lethal murine model. Blood 96: 1157, 2000
Woolley DE: Collagenolytic mechanisms in tumor cell invasion. Cancer Metast Rev 3: 361–372, 1984
Reich R, Thompson EW, Iwamoto YY et al.: Effects of inhibitors of plasminogen activator, serine proteases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 48: 3307–3312, 1988
Ossowski L, Clunie G, Masucci MT et al.: In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Bio 115: 1107–1112, 1991
Abe T, Mori T, Kohno K et al.: Expression of 72-Dka type IV collagenase and invasion activity of human glioma cells. Clin Exp Metastasis 12: 296–304, 1994
Declerck YA, Perez N, Shimada HH et al.: Inhibition of invasion and metastatis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52: 701–708, 1992
Christensen L, Simonsen ACW, Heegaard CW et al.: Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and ą-2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66: 441–452, 1996
Fabrini MS, Carpani D, Bello-Rivero I et al.: The aminoterminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated. FASEB J 11: 1169–1176, 1997
Grøndahl-Hansen J, Peters HA, van Putten WLJ et al.: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1: 1079–1087, 1995
Blasi F: uPA, uPAR, PAI-1:Key intersection of proteolytic, adhesive and chemotactic highways? Trends Immunol Today18: 415–417, 1997
Roldan AL, Cubellis MV, Masucci MT et al.: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467–474, 1990
Behrendt N, Rønne E, Ploug M et al.: The human receptor for urokinase plasminogen activator. J Biol Chem 265: 6453–6460, 1990
Høyer-Hansen G, Rønne E, Behrendt N et al.: Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 267: 18224–18229, 1992
Waltz DA, Chapman HA: Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269: 14746–14750, 1994
Wei Y, Waltz DA, Rao N et al.: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380–32388, 1994
Resnati M, Guttinger M, Valcamonica S et al.: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15: 1572–1582, 1996
De Vries TJ, Mooy CM, Van Balken MR et al.: Components of the plasminogen activation system in uveal melanoma – a clinico-pathological study. J Pathol 175: 59–67, 1995
Versgaet HW, Sier CF, Ganesh S et al.: Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer 31A: 1105–1109, 1995
Crowley CW, Cohen RL, Lucas BK et al.: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90: 5021–5025, 1993
Mori T, Abe T, Wakabayashi Y et al.: Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. J Neuro-Oncol 46: 115–123, 2000
Vallera DA, Li C, Jin N et al.: Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst 94: 597–606, 2002
Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4–6, 1990
Olson TA, Mohanraj D, Roy S, Ramakrishnan S: Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor–toxin conjugate. Int J Cancer 73: 865–870, 1997
Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275: 547–550, 1997
Beitz JG, Davol-Lewis P, Clark JW, Kato J, Medina M, Frackelton AR, Lappi DA, Baird A, Calabresi P: Antitumor activity of basic FGF-saporin mitotoxin in vitro and in vivo. Cancer Res 52: 227–230, 1992
Burrows FJ, Thorpe PE: Eradication of large solid tumors in mice with an immunotoxin directed against the tumor vasculature. Proc Natl Acad Sci 90: 8996–9000, 1993
Gawlak SL, Pastan I, Siegall CB. Basic fibroblast growth factor. Pseudomonas exotoxin chimeric proteins: comparison with acidic fibroblast growth factor–Pseudomonas exotoxin. Bioconjug Chem 4: 483–489, 1993
Ramakrishnan S, Olson TA, Bauch VL, Mohanraj D. Vascular endothelial growth factor–toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56: 1324–1330, 1996
Solberg H, Ploug M, Høyer-Hansen G et al.: The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem 49: 237–246, 2001
Fulcher S, Lui GM, Houston LL et al.: Use of immunotoxin to inhibit proliferating human corneal endothelium. Invest Opthalmol Vis Sci 29: 755–759, 1988
Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY: Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 5: 985–990, 1999
Debinski W, Obiri NI, Powers SK et al.: Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed 75 of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1: 1253–1258, 1995
Zurawski G, de Vries JE: Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15: 1994
Brown KD, Zurawski SM, Mosmann TR, Zurawski G: Afamily of small inducible proteins secreted by leukocytes are members of a new super-family that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 142: 679, 1989
Minty A, Chalon P, Derocq J-M, Dumont X, Guillemot J-C, Kaghad M, Labit C, Leplatois P, Liauzum P, Miloux B, Minty C, Casekkas P, Loison G, Lupker J, Shire D, Ferrara P, Caput D: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362: 248, 1993
Obiri NI, Leland P, Murata T, Debinski W, Puri RK: The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol 158: 756–764, 1997
Debinski W: An immune regulatory cytokine receptor and glioblastoma multiforme an unexpected link. Crit Rev Oncog 9: 255–268, 1998
Li C, Hall WA, Jin N et al.: Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng 15: 419–427, 2002
Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6: 2157–2165, 2000
Debinski W, Gibo DM, Hulet SW et al.: Receptor for interleukin 13 is a marker and therapeutic target for human high grade gliomas. Clin Cancer Res 5: 985–990, 1999
Hussain SR, Joshi BH, Puri RK et al.: Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92: 168–175, 2001
Debinski W: Local treatment of brain tumors with targeted chimera cytotoxic proteins. cancer Invest 20(5–6): 801–809, 2002 (Review)
Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3: 1362–1368, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rustamzadeh, E., Li, C., Doumbia, S. et al. Targeting the Over-Expressed Urokinase-Type Plasminogen Activator Receptor on Glioblastoma Multiforme. J Neurooncol 65, 63–75 (2003). https://doi.org/10.1023/A:1026238331739
Issue Date:
DOI: https://doi.org/10.1023/A:1026238331739